Definium Therapeutics (NASDAQ:DFTX) Issues Earnings Results

Key Points

• Definium Therapeutics missed earnings expectations, reporting a quarterly loss of $0.71 per share versus analysts’ estimate of a $0.48 loss.
• Three pivotal phase III readouts for DT120 are coming soon, with EMERGE expected later this quarter and VOYAGE and PANORAMA due in early and late Q3; management also signaled a potential NDA filing if results are positive.
• The company ended Q1 with $373.4 million in cash and investments, which it says should fund operations through multiple clinical milestones and into 2028, despite a rising expense base and a wider net loss.

Definium Therapeutics (NASDAQ:DFTX - Get Free Report) posted its earnings results on Thursday. The company reported ($0.71) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.23), FiscalAI reports.

Here are the key takeaways from Definium Therapeutics' conference call:

• Three pivotal DT120 ODT phase III readouts are imminent — EMERGE (MDD) top-line later this quarter, and VOYAGE and PANORAMA (both GAD) expected in early and late Q3 respectively, with Breakthrough Therapy designation for DT120 in GAD and an NDA submission planned subject to positive data.
• All pivotal trials are near complete (EMERGE 149 enrolled; VOYAGE 214; PANORAMA >200) and were powered around a 5‑point placebo‑adjusted difference (VOYAGE/PANORAMA >99% power; EMERGE 80% with ~3‑point significance threshold), which management says targets clinically meaningful and durable single‑dose effects.
• Each study includes a Part B with up to one year of follow‑up and up to four open‑label retreatments triggered at moderate symptoms, intended to characterize retreatment patterns, durability, and longer‑term safety for potential labeling discussions.
• The company ended Q1 with $373.4 million in cash and investments, which management believes provides runway to fund planned operations through multiple pivotal readouts and into 2028.
• Near‑term spend ramped materially — Q1 R&D rose to $41.5M and G&A to $17.7M versus prior year — contributing to a wider net loss of $77.1M, with a $20M quarterly impact from warrant fair‑value movement, indicating higher cash burn and elevated execution costs ahead.

Definium Therapeutics Stock Performance

NASDAQ DFTX traded down $1.15 during trading hours on Friday, reaching $22.05. 2,203,452 shares of the company were exchanged, compared to its average volume of 1,963,772. Definium Therapeutics has a 1 year low of $6.03 and a 1 year high of $26.25. The business's 50 day simple moving average is $19.98 and its 200-day simple moving average is $16.05. The company has a quick ratio of 6.29, a current ratio of 6.29 and a debt-to-equity ratio of 0.12. The stock has a market capitalization of $2.20 billion, a P/E ratio of -8.86 and a beta of 2.37.

Analyst Ratings Changes

A number of research firms have weighed in on DFTX. HC Wainwright boosted their target price on shares of Definium Therapeutics from $55.00 to $70.00 and gave the stock a "buy" rating in a report on Monday, March 2nd. Oppenheimer reissued an "outperform" rating and set a $40.00 target price on shares of Definium Therapeutics in a report on Thursday, April 23rd. Royal Bank Of Canada boosted their price target on shares of Definium Therapeutics from $20.00 to $36.00 and gave the stock an "outperform" rating in a research report on Friday, January 23rd. Canaccord Genuity Group set a $38.00 price target on shares of Definium Therapeutics and gave the stock a "buy" rating in a research report on Thursday, April 16th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Definium Therapeutics in a research report on Tuesday, April 21st. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $37.92.

Hedge Funds Weigh In On Definium Therapeutics

Hedge funds have recently bought and sold shares of the company. Russell Investments Group Ltd. raised its stake in Definium Therapeutics by 110.4% in the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company's stock valued at $25,000 after purchasing an additional 2,003 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in Definium Therapeutics by 56.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company's stock valued at $55,000 after buying an additional 3,020 shares during the last quarter. Caxton Associates LLP bought a new stake in Definium Therapeutics in the 3rd quarter worth $126,000. Mercer Global Advisors Inc. ADV grew its holdings in Definium Therapeutics by 10.5% in the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 21,931 shares of the company's stock worth $259,000 after acquiring an additional 2,079 shares during the last quarter. Finally, Scientech Research LLC bought a new stake in Definium Therapeutics in the 3rd quarter worth $286,000. Hedge funds and other institutional investors own 27.91% of the company's stock.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.